25 May 2013
Keywords: Novartis, Bexsero, Meningococcal infections, Vaccine
Article | 10 June 2011
Swiss drug major Novartis (NVN: VX) says that new data from a pivotal study in more than 1,800 infants show that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 June 2011
24 May 2013
© 2013 thepharmaletter.com